Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel Lipid Tablet in mCRPC
NCT06890832Phase 2Not yet recruiting
- Sponsor
- Jina Pharmaceuticals, Inc.
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Allosteric Modulators
01
Overview
A Phase 2 trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Jina Pharmaceuticals, Inc.. Planned start May 2025; status: not yet recruiting.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06890832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890832.